Form 4: Aclaris Therapeutics Chief Scientific Officer Reports Stock Transaction

Aclaris Therapeutics' Chief Scientific Officer, Joseph Monahan, reported the disposition of 15,000 shares of common stock on December 10, 2024.

Summary

• Joseph Monahan, the Chief Scientific Officer of Aclaris Therapeutics, Inc., filed a Form 4 indicating a change in beneficial ownership of company stock.
• On December 10, 2024, Mr. Monahan disposed of 15,000 shares of Aclaris Therapeutics common stock.
• The disposition was a gift, and the price per share was $0.
• Following the transaction, Mr. Monahan directly owns 171,783 shares of common stock.
• Additionally, Mr. Monahan indirectly owns 193 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock transaction by an officer, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company officer, which is common in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for company insiders in publicly traded companies, including those in the pharmaceutical sector like Aclaris Therapeutics.
• Similar filings are made by executives at companies like Regeneron, Vertex Pharmaceuticals, and Incyte when they trade company stock.
• The reporting requirements are consistent across all publicly traded companies in the US.

Stakeholder Impact

• The transaction may have a minor impact on shareholders, as it reflects a change in insider ownership.
• The impact on other stakeholders is likely to be minimal.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Form 4, Beneficial Ownership, Stock Transaction, Joseph Monahan, Chief Scientific Officer, SEC Filing